The creatinine-to-cystatin C ratio (CCR) is an emerging marker of muscle mass, which influences the progression of nonalcoholic fatty liver disease (NAFLD). The gene discussed is CST3; the disease is metabolic dysfunction-associated steatotic liver disease.